Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection

INTRODUCTION: Nirsevimab is an extended half-life (M252Y/S254T/T256E [YTE]-modified) monoclonal antibody to the pre-fusion conformation of the respiratory syncytial virus (RSV) Fusion protein, with established efficacy in preventing RSV-associated lower respiratory tract infection in infants for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Brady, Tyler, Cayatte, Corinne, Roe, Tiffany L., Speer, Scott D., Ji, Hong, Machiesky, LeeAnn, Zhang, Tianhui, Wilkins, Deidre, Tuffy, Kevin M., Kelly, Elizabeth J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600457/
https://www.ncbi.nlm.nih.gov/pubmed/37901217
http://dx.doi.org/10.3389/fimmu.2023.1283120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600457/
https://www.ncbi.nlm.nih.gov/pubmed/37901217
http://dx.doi.org/10.3389/fimmu.2023.1283120

Ejemplares similares